Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J 71(3):209–249. https://doi.org/10.3322/caac.21660
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C (2017) Progress and prospects of early detection in lung cancer. Open Biol 7(9):1–12. https://doi.org/10.1098/rsob.170070
Bracht JWP, Karachaliou N, Berenguer J, Pedraz-Valdunciel C, Filipska M, Codony-Servat C, Codony-Servat J, Rosell R (2019) Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). Int J Biol Sci 15(12):2607–2614. https://doi.org/10.7150/ijbs.32889
Article CAS PubMed PubMed Central Google Scholar
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol 4(11):1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969
Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015) Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16(4):e165-172. https://doi.org/10.1016/s1470-2045(14)71180-5
Article CAS PubMed PubMed Central Google Scholar
Lee S, Rauch J, Kolch W (2020) Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 21(3):1102. https://doi.org/10.3390/ijms21031102
Article CAS PubMed PubMed Central Google Scholar
Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, Yang X (2018) Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis 9(2):129. https://doi.org/10.1038/s41419-017-0120-6
Article CAS PubMed PubMed Central Google Scholar
Chen B, Lai J, Dai D, Chen R, Liao N, Gao G, Tang H (2020) PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. Ther Adv Med Oncol 12:1758835920974212. https://doi.org/10.1177/1758835920974212
Article CAS PubMed PubMed Central Google Scholar
Ding L, Chen X, Xu X, Qian Y, Liang G, Yao F, Yao Z, Wu H, Zhang J, He Q, Yang B (2019) PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3. Cancer Immunol Res 7(1):136–149. https://doi.org/10.1158/2326-6066.Cir-18-0071
Article CAS PubMed Google Scholar
Dellomo AJ, Abbotts R, Eberly CL, Karbowski M, Baer MR, Kingsbury TJ, Rassool FV (2022) PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. Transl Oncol 15(1):101283. https://doi.org/10.1016/j.tranon.2021.101283
Article CAS PubMed Google Scholar
Fang Z, Gong C, Ye Z, Wang W, Zhu M, Hu Y, Liu Z, Zhou W, Li H (2022) TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1. DNA Repair 111:103278. https://doi.org/10.1016/j.dnarep.2022.103278
Article CAS PubMed Google Scholar
de Souza França PD, Guru N, Kostolansky AR, Mauguen A, Pirovano G, Kossatz S, Roberts S, Abrahão M, Patel SG, Park KJ, Reiner T, Jewell E (2021) PARP1: a potential molecular marker to identify cancer during colposcopy procedures. J Nucl Med 62(7):941–948. https://doi.org/10.2967/jnumed.120.253575
Article CAS PubMed Google Scholar
Montaldi AP, Lima SCG, Godoy P, Xavier DJ, Sakamoto-Hojo ET (2020) PARP-1 inhibition sensitizes temozolomide-treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncol Rep 44(5):2275–2287. https://doi.org/10.3892/or.2020.7756
Article CAS PubMed Google Scholar
Wang Q, Xiong J, Qiu D, Zhao X, Yan D, Xu W, Wang Z, Chen Q, Panday S, Li A, Wang S, Zhou J (2017) Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. Int J Biochem Cell Biol 92:164–172. https://doi.org/10.1016/j.biocel.2017.08.001
Article CAS PubMed Google Scholar
Zhang Z, Lian X, Xie W, Quan J, Liao M, Wu Y, Yang ZZ, Wang G (2020) Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Sci Rep 10(1):20924. https://doi.org/10.1038/s41598-020-77908-z
Article CAS PubMed PubMed Central Google Scholar
Erguven M, Bilir A, Yazihan N, Ermis E, Sabanci A, Aktas E, Aras Y, Alpman V (2011) Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int 11(1):18. https://doi.org/10.1186/1475-2867-11-18
Article CAS PubMed PubMed Central Google Scholar
Tong Y, Wang R, Liu X, Tian M, Wang Y, Cui Y, Zou W, Zhao Y (2021) Zuojin pill ameliorates chronic atrophic gastritis induced by MNNG through TGF-β1/PI3K/Akt axis. J Ethnopharmacol 271:113893. https://doi.org/10.1016/j.jep.2021.113893
Article CAS PubMed Google Scholar
Jeong KY, Park MH (2021) The significance of targeting poly (ADP-ribose) polymerase-1 in pancreatic cancer for providing a new therapeutic paradigm. Int J Mol Sci 22(7):3509. https://doi.org/10.3390/ijms22073509
Article CAS PubMed PubMed Central Google Scholar
Engbrecht M, Mangerich A (2020) The nucleolus and PARP1 in cancer biology. Cancers (Basel) 12(7):1813. https://doi.org/10.3390/cancers12071813
Article CAS PubMed Google Scholar
Yamashita S, Tanaka M, Ida C, Kouyama K, Nakae S, Matsuki T, Tsuda M, Shirai T, Kamemura K, Nishi Y, Moss J, Miwa M (2022) Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation. Exp Cell Res 417(1):113163. https://doi.org/10.1016/j.yexcr.2022.113163
Article CAS PubMed PubMed Central Google Scholar
Choi EB, Yang AY, Kim SC, Lee J, Choi JK, Choi C, Kim MY (2016) PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair. Oncogene 35(35):4569–4579. https://doi.org/10.1038/onc.2016.3
Article CAS PubMed Google Scholar
Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H (2019) Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity. Cell Rep 27(12):3422-3432.e3424. https://doi.org/10.1016/j.celrep.2019.05.058
Article CAS PubMed PubMed Central Google Scholar
Zhang H, Wang Y, Wu H, Zhou S, Li S, Meng X, Tao R, Yu J (2022) Olaparib combined with dacomitinib in osimertinib-resistant brain and leptomeningeal metastases from non-small cell lung cancer: a case report and systematic review. Front Oncol 12:877279. https://doi.org/10.3389/fonc.2022.877279
Article PubMed PubMed Central Google Scholar
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):26. https://doi.org/10.1186/s12943-019-0954-x
Article PubMed PubMed Central Google Scholar
Wang L, Zhou Y, Jiang L, Lu L, Dai T, Li A, Chen Y, Zhang L (2021) CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway. Mol Cancer 20(1):43. https://doi.org/10.1186/s12943-021-01332-8
Article CAS PubMed PubMed Central Google Scholar
Wang Z, Jia L, Sun Y, Li C, Zhang L, Wang X, Chen H (2021) CORO1C is associated with poor prognosis and promotes metastasis through PI3K/AKT pathway in colorectal cancer. Front Mol Biosci 8:682594. https://doi.org/10.3389/fmolb.2021.682594
Article CAS PubMed PubMed Central Google Scholar
Wu MD, Zhang YY, Yi SY, Sun BB, Lan J, Jiang HM, Hao GP (2022) Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells. J Cell Mol Med 26(5):1606–1620. https://doi.org/10.1111/jcmm.17202
Article CAS PubMed PubMed Central Google Scholar
Verret B, Cortes J, Bachelot T, Andre F, Arnedos M (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30(Suppl_10):x12–x20. https://doi.org/10.1093/annonc/mdz381
Article CAS PubMed PubMed Central Google Scholar
Dong C, Wu J, Chen Y, Nie J, Chen C (2021) Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 12:628690. https://doi.org/10.3389/fphar.2021.628690
Article CAS PubMed PubMed Central Google Scholar
Wang W, Xia X, Chen K, Chen M, Meng Y, Lv D, Yang H (2021) Reduced PHLPP expression leads to EGFR-TKI resistance in lung cancer by activating PI3K-AKT and MAPK-ERK dual signaling. Front Oncol 11:665045. https://doi.org/10.3389/fonc.2021.665045
留言 (0)